Ultrarapid opiate detoxification: A review

Canadian Journal of Anesthesia

Volumn 50, Issue 7, 2003, Pages 663-671

  Kaye, Alan D ^a   Gevirtz, Clifford ^a   Bosscher, Hemmo A ^b   Duke, Joe B ^b   Frost, Elizabeth A M ^a   Richards, Todd A ^b   Fields, Aaron M ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANESTHETIC AGENT; BUPRENORPHINE; CLONAZEPAM; CLONIDINE; DEXMEDETOMIDINE; DIAMORPHINE; DIAZEPAM; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; INHALATION ANESTHETIC AGENT; LOPERAMIDE; MELATONIN; METHADONE; METHOTREXATE; MIDAZOLAM; NALMEFENE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONIST; OCTREOTIDE; ONDANSETRON; OPIATE; OPIATE ANTAGONIST; PERCOCET; PERCODAN; PROPOFOL; RANITIDINE; TRAZODONE; UNINDEXED DRUG;

ANESTHESIA INDUCTION; DIARRHEA; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; EXPERIENCE; GENERAL ANESTHESIA; GOVERNMENT; HEALTH CARE COST; HEROIN DEPENDENCE; HUMAN; HYPNOSIS; INCIDENCE; INSOMNIA; MEDICAL LITERATURE; MEDICAL SCHOOL; OPIATE ADDICTION; PATIENT ATTITUDE; PATIENT CARE; PATIENT SELECTION; PEER REVIEW; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; TREATMENT FAILURE; UNITED STATES; VOMITING; WITHDRAWAL SYNDROME;

EID: 0142242300     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03018708     Document Type: Review

References (64)

1. http://www.drugabuse.gov/Infofax/nationtrends.html.
2. Zwillich T. Prescription drug abuse said to be on the rise. Reuters 2001; April 10.
3. http://www.nlm.nih.gov/medlineplus/news/fullstory_1171.html.
4. www.drugabuse.gov/ResearchReports/Heroin/heroin2.html#scope
5. Stafford K, Gomes AB, Shen J, Yoburn BC. mu-opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav 2001; 69: 233-7.
6. Gold MS. Opiate addiction and locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. Psychiatr Clin North Am 1993; 16: 61-73.
7. www.drugabuse.gov/Infofax/heroin.html.
8. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 2000; 909: 170-85.
9. Spanagel R. Is there a pharmacological basis for therapy with rapid opioid detoxification? Lancet 1999; 354: 2017-8.
10. Roizen MF. How does μ-opioid receptor blockade work in addicted patients? Anesthesiology 1998; 88: 1142-3.
11. Bovill JG. Opioid detoxification under anaesthesia. Eur J Anaesthesiol 2000; 17: 657-61.
12. Nestler EJ. Under siege: the brain on opiates. Neuron 1996; 16: 897-900.
13. Blendy JA, Maldonado R. Genetic analysis of drug addiction: the role of cAMP response element binding protein. J Mol Med 1998; 76: 104-10.
14. Maldonado R, Blendy JA, Tzavara E, et al. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 1996; 273: 657-9.
15. Maldonado R, Stinus L, Koob GF, et al. Neurobiological Mechanisms of Opiate Withdrawal. New York: USA Springer; 1996.
16. Mattick RP, Hall W. Are detoxification programmes effective? Lancet 1996; 347: 97-100.
17. Jasinski DR. Tolerance and dependence to opiates. Acta Anaesthesiol Scand 1997; 41: 184-6.
18. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13: 4-17.
19. O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet 1996; 347: 237-40.
20. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend 2000; 58: 85-92.
21. Fudula PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opiate addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525-34.
22. Alling FA, Johnson BD, Elmoghazy E. Cranial electrostimulation (CES) use in the detoxification of opiate-dependent patients. J Subst Abuse Treat 1990; 7: 173-80.
23. Poshychinda V. Thailand: treatment at the Tam Kraborg Temple. In: Edwards G, Arif A (Eds.). Drug Problems in the Sociocultural Context: a Basis for Policies and Program Planning. Geneva: World Health Organization; 1980: 121-5.
24. Kienbaum P, Scherbaum N, Thurauf N, Michel MC, Gastpar M, Peters J. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. Crit Care Med 2000; 28: 969-76.
25. Christie MJ, Williams JT, Osborne PB, Bellchambers CE. Where is the locus in opioid withdrawal? Trends Pharmacol Sci 1997; 18: 134-40.
26. Keinbaum P, Thurauf N, Michel MC, Scherbaum N, Gastpar M, Peters J. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after μ-opioid receptor blockade in opioid addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology 1998; 88: 1154-61.
27. Langer SZ. Presynaptic regulation of release of catecholamines. Pharmacol Rev 1981; 32: 337-62.
28. Gold MS, Redmond DE Jr, Kleber HD. Noradrenergic hyperactivity in opiate withdrawal supported clonidine reversal of opiate withdrawal. Am J Psychiatry 1979; 136: 100-2.
29. Diaz A, Pazos A, Florez J, Ayesta FJ, Santana V, Hurle MA. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience 2002; 112: 345-53.
30. Charney DS, Heninger GR, Kleber D. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry 1986; 143: 831-7.
31. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353: 221-6.
32. Farrel M. Opioid withdrawal. Addiction 1994; 89: 1471-7.
33. Senft RA. Experience with clonidine-naltrexone for rapid opiate detoxification. J Subst Abuse Treat 1991; 8: 257-9.
34. Resnick RB, Kestenbaum RS, Washton A. Poole D. Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone. Clin Pharmacol Ther 1977; 21: 409-13.
35. Loimer N, Schmid R, Lenz K, Presslich O, Grunberger J. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990; 157: 748-52.
36. Presslich O, Loimer N. Opiate detoxification under general anesthesia by large doses of naloxone. J Toxicol Clin Toxicol 1989; 27: 263-70.
37. Simon DL. Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art. J Addict Dis 1997; 16: 103-22.
38. Legarda JJ, Gossop M. A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug Alcohol Depend 1994; 35: 91-3.
39. Rasmussen K, Beitner-Johnson DB, Krystal JH, Aghajanian GK, Nestler EJ. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci 1990; 10: 2308-17.
40. Gold CG, Cullen DJ, Gonzales S, Houtmeyers D, Dwyer MJ. Rapid opioid detoxification during general anesthesia. Anesthesiology 1999; 91: 1639-47.
41. Lorenzi P, Marsili M, Boncinelli S, et al. Searching for a general anaesthesia protocol for rapid detoxification from opioids. Eur J Anaesthesiol 1999; 16: 719-27.
42. Cucchia AT, Monnat M, Spagnoli J, Ferrero F, Bertschy G. Ultra-rapid opiate detoxification using deep sedation with midazolam: short and long-term results. Drug Alcohol Depend 1998; 52: 243-50.
43. Gevirtz C, Frost E. Ultra rapid opiate detoxification current concepts. Curr Opin Clin Exp Res 2000; 2: 151-68.
44. McDonald T, Berkowitz R, Hoffman WE. Plasma naltrexone during opioid detoxification. J Addict Dis 2000: 19: 59-64.
45. Walters CL, Aston-Jones G, Druhan JP. Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist. Neuropsychopharmacology 2000; 23: 307-15.
46. McDonald T, Berkowitz R, Hoffman WE. Median EEG frequency is more sensitive to increases in sympathetic activity than bispectral index. J Neurosurg Anesthesiol 1999; 11: 255-9.
47. Tweedle D, Nightingale P. Anesthesia and gastrointestinal surgery. Acta Chir Scand Suppl 1989; 550: 131-9.
48. Brewer C. Ultra rapid, antagonist-precipitated opiate detoxification under general anaesthesia or sedation. Addiction Biol 1997; 2: 291-302.
49. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996; 52: 773-94.
50. Madsen BW, Albuquerque EX. The narcotic antagonist naltrexone has a biphasic effect on the nicotinic acetylcholine receptor. FEBS Lett 1985; 182: 20-4.
51. Kienbaum P, Thuauf N, Michel MC, Scherbaum N, Gastpar M, Peters J. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology 1998; 1154-161.
52. Hoffman WE, Berkowitz R, McDonald T, Hass F. Ultra-rapid opioid detoxification increases spontaneous ventilation. J Clin Anesth 1998; 10: 372-6.
53. McDonald T, Hoffman WE, Berkowitz R, Cunningham F, Cooke B. Heart rate variability and plasma catecholamines in patients during opioid detoxification. J Neurosurg Anesthesiol 1999; 11: 195-9.
54. Manilli P, De Risio S, Pozzi G, Janiri L, De Giacomo M. Serendipitous rapid detoxification from opiates: the importance of time-dependent processes. Addiction 1999; 94: 589-91.
55. Ronnback L, Eriksson PS, Zeuchner J, Rosengren L, Wronski A. Aspects of abstinence after morphine ingestion. Pharmacol Biochem Behav 1987; 28: 87-93.
56. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13: 293-308.
57. Kosten TR, Kreek MJ, Ragunath J, Kleber HD. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry 1986; 21: 217-20.
58. Dunlap CE 3rd, Valego NK, Rose JC. Comparison of high-dose opioid antagonist effects on ovine fetal cardiovascular function Dev Pharmacol Ther 1989; 13: 28-37.
59. Jepsen PW. Naltrexone. An opioid antagonist to support the drug-free state in previous opioid addicts having stopped the habit (Danish). Ugeskr Laeger 1990; 152: 2546-9.
60. Chanmugam AS, Hengeller M, Ezenkwele U. Development of rhabdomyolysis after rapid opioid detoxification with subcutaneous naltrexone maintenance therapy. Acad Emerg Med 2000; 7: 303-5.
61. Burleigh DE. Opioid and non-opioid actions of loperamide on cholinergic nerve function in human isolated colon. Eur J Pharmacol 1988; 152: 39-46.
62. Staedt J, Wassmuth F, Stoppe G, et al. Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci 1996, 246: 305-9.
63. Millman RP. Therapy of insomnia. Med Health R I 2002; 85: 99-100.
64. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339-46.